March 12, 2021 | I Peace, Inc

News

I Peace, Inc. honored in BioSpectrum Asia Excellence Award 2022 with “Special Recognition in Cell Therapy”

•

December 22, 2022

•

Uncategorized

I Peace partners with the California Institute for Regenerative Medicine [CIRM]

•

November 1, 2022

•

Other, Other

CEO Koji Tanabe presents at the 2022 International Summit Forum on Cell Therapy and Regenerative Medicine in Taiwan

•

October 28, 2022

•

Events

GMP cell CDMO I Peace, Inc. in collaboration with universities successfully converted human dermal fibroblasts into oligodendrocyte by direct reprogramming

•

September 20, 2022

•

Uncategorized

I Peace in the News – the Nikkei on, 2022

•

August 3, 2022

•

Media

A new automated iPSC high-throughput induction system to induce thousands of iPSC lines simultaneously
To be presented at ISSCR 2022 Annual Meeting

•

June 15, 2022

•

Press, Press, Press, Press, Press, Press

I Peace accelerates allogeneic iPSC-derived cell therapies with a high throughput method to identify a large number of donors with specific HLA haplotypes

•

May 12, 2022

•

Uncategorized

I Peace triples GMP cell manufacturing by expanding CDMO facility

•

March 14, 2022

•

Uncategorized

I Peace’s Cell Manufacturing Facility “Peace Engine-Kyoto”now registered as U.S. FDA Drug Establishment

•

January 26, 2022

•

Uncategorized

[Summary of Research]Anti-cancer therapeutic potential of tumoricidal T cells regenerated from tumor-infiltrating lymphocyte-derived iPS cells

•

October 19, 2021

•

Uncategorized

Reach out to us to learn more